Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Coley initiates phase I/II trials of CpG-7909 for cancer

April 24, 2000

Preclinical results for Avax's AC Vaccine technology in breast cancer presented at AACR

April 14, 2000

SuperGen and AVI BioPharma establish marketing agreement for Avicine

April 11, 2000

Zadaxin plus chemotherapy shows promise in malignant melanoma

April 11, 2000

M-Vax shown to induce T-cell-mediated immune reactions in metastatic melanoma study

April 11, 2000

Dendreon describes preparation and use of apoptosis-inducing HLA-DR-specific MAbs

April 10, 2000

Health Canada approves Rituxan for treatment of NHL

April 7, 2000

Oncolytics Biotech's pilot canine study of Reolysin shows measurable tumor response

April 4, 2000

Avax begins phase II study of M-Vax in stage IV metastatic melanoma

April 3, 2000

AltaRex presents clinical plan for OvaRex at BIO 2000 annual meeting

March 30, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...